Most ALS research today hinges on a simple question: how do we find reliable biomarkers that can unlock faster, more targeted drug development?
Dr. Michael Benatar, an international leader in neuromuscular research unpacks the complex world of biomarkers, revealing why identifying and validating these biological tools has been such a challenge and why they are key to transforming ALS treatment.
You'll discover how neurofilament light chain (NFL) is emerging as a promising prognostic and response biomarker, capable of predicting disease progress and evaluating therapy impact in real time. Dr. Benatar shares groundbreaking insights from his work on pre-symptomatic ALS and the CReATe Consortium, illustrating the steps from discovery to clinical validation. He breaks down the different types of biomarkers: diagnostic, prognostic, disease progression, predictive, and response, demystifying how each can shape your healthcare journey and research.
If you're a person living with ALS, caregiver, researcher, or advocate eager for better treatments, this episode is essential. Don’t miss this vital conversation that could change how we fight ALS.
Podden och tillhörande omslagsbild på den här sidan tillhör
North Star ALS. Innehållet i podden är skapat av North Star ALS och inte av,
eller tillsammans med, Poddtoppen.
